Johnson & Johnson has proposed a $5.5 billion settlement to resolve nearly all remaining U.S. lawsuits alleging its talc-based baby powder and other products caused ovarian cancer, while continuing to deny the claims.
Johnson & Johnson has unveiled a proposed $5.5 billion settlement intended to resolve most remaining U.S. lawsuits alleging that its talc-based products caused ovarian cancer. The agreement is contingent on broad claimant participation, and the company maintains that decades of scientific research do not support allegations that its products cause cancer.
Johnson & Johnson (J&J) has proposed a $5.5 billion settlement to resolve the majority of U.S. lawsuits alleging that its talc-based baby powder and other consumer products caused ovarian cancer, marking the company’s latest effort to end one of the largest product liability disputes in U.S. history.
The proposed agreement covers approximately 76,000 remaining claims in federal and state courts. However, it will only take effect if at least 95% of eligible claimants agree to participate, making it a conditional settlement rather than a finalized agreement.
Johnson & Johnson said the proposal follows recent court developments that raised questions about whether plaintiffs could establish a direct scientific link between individual ovarian cancer cases and the company’s talc products. The company emphasized that the settlement is intended to end years of costly litigation rather than acknowledge liability.
The healthcare company continues to deny that its talc products cause cancer or contain asbestos. It maintains that decades of scientific studies and regulatory reviews support the safety of cosmetic talc products and that the lawsuits lack scientific merit.
If the proposal receives sufficient support from claimants, Johnson & Johnson plans to make an initial payment of up to $3 billion in 2027, with additional payments beginning no earlier than 2028. The company said the agreement would allow it to put more than 15 years of litigation behind it and focus on its pharmaceutical and medical technology businesses.
The proposed settlement follows three unsuccessful attempts by Johnson & Johnson to resolve the litigation through bankruptcy proceedings involving a subsidiary. U.S. courts rejected those efforts, leading the company to pursue a voluntary settlement with plaintiffs instead.
Why It Matters
The proposed settlement could significantly reduce one of the largest mass tort cases in the U.S. healthcare sector while highlighting the ongoing debate between scientific evidence and product liability litigation. Although the agreement would resolve most current ovarian cancer claims if approved, Johnson & Johnson’s denial of liability means the scientific and legal discussion surrounding talc products is likely to continue.
Frequently Asked Questions
Has Johnson & Johnson admitted its talc products cause cancer?
No. The company continues to deny that its talc-based products cause ovarian cancer or contain asbestos. It says the settlement is intended to resolve litigation, not to admit wrongdoing.
Is the $5.5 billion settlement final?
No. The proposal becomes effective only if at least 95% of eligible claimants agree to participate. Until then, it remains a proposed settlement.
How many lawsuits are covered?
Johnson & Johnson says the proposal would resolve approximately 76,000 remaining ovarian cancer claims pending in U.S. federal and state courts.
What happens next?
Claimants represented by participating law firms will decide whether to join the settlement. If the required participation threshold is reached, payments are expected to begin in 2027.
Sources: Johnson & Johnson, Reuters, Associated Press
